2026-10-15T07:32:30Z https://api.figshare.com/v2/oai

oai:figshare.com:article/32006382 2026-04-16T10:02:07Z category_27241 portal_753 item_type_3 month_year_04_2026

Actinium-225, prostate specific membrane antigen (PSMA), and poly(lactic-co-glycolic acid) (PLGA) nanoparticles for targeted alpha therapy of prostate cancer Yonwaba Mzizi (23709297) Other health sciences not elsewhere classified Prostate cancer Actinium-225 Nano drug delivery system Targeted alpha therapy Nanoparticles Prostate specific membrane antigen (PSMA) Poly(lactic-co-glycolic acid) (PLGA) SDG 3 Good health and wellbeing <p dir="ltr">The purpose of this research was to develop a 225Ac-targeted alpha therapy delivery vehicle using PLGA-chitosan-folic acid-based nanoparticles for tumour selectivity. 8 to 10 MBq of 225Ac-PSMA617-TFA radiopharmaceuticals were produced. The quality controls were monitored, the radiochemical purity was determined in triplicate using a cut-and-count method, where the segments of the iTLC TSA strips were counted<br>in a gamma well counter in the Francium-221 (221Fr) energy window, 218 keV. The data set includes tables and summaries of the research conducted. This was a prospective quantitative experimental study that included the following experiments:</p><ul><li>Radiolabeling of 225Ac PSMA</li><li>Preparation of PLGA nanoparticles</li><li>Functionalising of PLGA nanoparticles with chitosan and folic acid</li><li>Encapsulation of 225Ac PSMA into PLGA-chitosan-folic acid nanoparticles</li><li>In-vitro drug release</li></ul><p><br></p> 2026-04-16T10:02:07Z Dataset Dataset 10.25403/UPresearchdata.32006382.v1 https://figshare.com/articles/dataset/Actinium-225_prostate_specific_membrane_antigen_PSMA_and_poly_lactic-co-glycolic_acid_PLGA_nanoparticles_for_targeted_alpha_therapy_of_prostate_cancer/32006382 CC BY 4.0